Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004 (Q28283745)

2

0 references

Shyam Sundar

6

object named as

Shyam Sundar

0 references

Piero Olliaro

1

object named as

Piero L Olliaro

0 references

author name string

Sibylle Gerstl

3

0 references

Astrid Aga Haaskjold

Lancet Infectious Diseases

4

0 references

language of work or name

English

0 references

publication date

December 2005

0 references

published in

0 references

volume

5

0 references

page(s)

763-74

0 references

issue

12

0 references

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Socio-economics of visceral leishmaniasis in Bihar (India)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Practical guide for the treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

The number needed to treat: a clinically useful nomogram in its proper context

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Calculating the number needed to treat for trials where the outcome is time to an event

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Oral miltefosine for Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Comparison of regimens of treatment with sodium stibogluconate in kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Amphotericin B for second-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Comparison of Regimes of Treatment of Antimony-Resistant Kala-Azar Patients: A Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Pentamidine-induced diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Trial of oral miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Oral treatment of visceral leishmaniasis with miltefosine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Short-course of oral miltefosine for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Sodium stibogluconate cardiotoxicity and safety of generics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Clinicoepidemiological study of drug resistance in Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021

A policy for leishmaniasis with respect to the prevention and control of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970296-6

7 January 2021